New clinical study "Potential of Moderate Whole Body Hyperthermia to Enhance Response (POWER)" at Charite University Berlin
A total of six different patient groups are included in the randomized phase II study, all with palliative therapy intentions (defined subgroups of patients with metastatic malignant melanoma, pancreatic ca, breast ca, sarcoma, head&neck ca, prostate ca).
Primary outcome measure is the change in the number of circulating tumor cells before therapy vs after therapy. Secondary outcome measures are among others tumor response, quality of life including depressions and fatigue, various biomarkers relevant for immune response and tumor microenvironment, survival and progression-free survival rate.
Responsibility for the study: PD Dr. med. Sebastian Zschaeck from Department of Radiation Oncology and Radiotherapy.
Get more detailed information in the clinical trial registry: https://clinicaltrials.gov/ct2/show/NCT05821166
Contacts for referring patients: